Royalty Pharma hands off $100M upfront for PureTech royalty on Karuna's schizophrenia hopeful

The company that spun out Karuna is cashing in on a $500 million deal with Royalty Pharma, just days after the biotech rolled out positive late-stage data and a nine-figure raise.